成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Autophagy Anti-infection Metabolic Enzyme/Protease Apoptosis
  3. Autophagy SARS-CoV Cytochrome P450 Apoptosis Parasite
  4. Cepharanthine

Cepharanthine 是一種可以從植物 Stephania?cephalantha ?Hayata中分離出來(lái)的天然產(chǎn)物。Cepharanthine 具有抗SARS-CoV-2 的活性。Cepharanthine 對(duì)病毒增殖有良好的抑制作用 (半數(shù)最大 (50%) 抑制濃度 (IC50) 和 90% 抑制濃度 (IC90) 值為 1.90 和 4.46?μM。Cepharanthine 還能有效逆轉(zhuǎn) K562 細(xì)胞中 P-gp 介導(dǎo)的多重耐藥性，并增強(qiáng)異種移植小鼠模型中抗癌藥物的敏感性。Cepharanthine 對(duì)人肝細(xì)胞色素 P450 酶 CYP3A4，CYP2E1 和 CYP2C9具有抑制作用。Cepharanthine 具有抗腫瘤、抗炎和鎮(zhèn)痛效果。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Cepharanthine Chemical Structure

Cepharanthine Chemical Structure

CAS No. : 481-49-2

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥550
In-stock
50 mg ￥500
In-stock
100 mg   詢價(jià)  
200 mg   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Cepharanthine:

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Cepharanthine is a natural product that can be isolated from the plant Stephania?cephalantha?Hayata. Cepharanthine has anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) activities. Cepharanthine has good effective in suppressing viral proliferation (half maximal (50%) inhibitory concentration (IC50) and 90% inhibitory concentration (IC90) values of 1.90 and 4.46?μM[1]. Cepharanthine can also effectively reverses P-gp-mediated multidrug resistance in K562 cells and increase enhances the sensitivity of anticancer agents in xenograft mice model[2][3]. Cepharanthine shows inhibitory effects of human liver cytochrome P450 enzymes CYP3A4, CYP2E1 and CYP2C9. Cepharanthine has antitumor, anti-inflammatory and antinociceptive effects[4][5][6][7][8].

IC50 & Target[4]

CYP3A4

16.29 μM (IC50)

CYP2E1

25.62 μM (IC50)

CYP2C9

24.57 μM (IC50)

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
A-431 ED50
2.1 μg/mL
Compound: 11
Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human A431 cells after 3 days by sulforhodamine B assay
[PMID: 8450319]
A549 IC50
5 μM
Compound: 7
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
Cytotoxicity against human A549 cells after 48 hrs by MTS assay
[PMID: 23621840]
A673 GI50
4.5 μM
Compound: Cepheranthine
Antiproliferative activity against human A673 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human A673 assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 33226219]
ECa-109 cell line IC50
> 10 μM
Compound: 7
Cytotoxicity against human ECA109 cells after 48 hrs by MTT assay
Cytotoxicity against human ECA109 cells after 48 hrs by MTT assay
[PMID: 23621840]
ECa-109 cell line IC50
436.7 nM
Compound: CEP
Reversal of VCR -resistance in human Eca-109 cells assessed as cell viability at 5 uM incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
Reversal of VCR -resistance in human Eca-109 cells assessed as cell viability at 5 uM incubated for 48 hrs by CCK-8 method (Rvb = 6830.0+/-537.0 nM)
[PMID: 36892076]
HCC1806 GI50
7.2 μM
Compound: Cepheranthine
Antiproliferative activity against human HCC1806 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HCC1806 assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 33226219]
HCC1937 GI50
6 μM
Compound: Cepheranthine
Antiproliferative activity against human HCC1937 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HCC1937 assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 33226219]
HCC70 GI50
5.8 μM
Compound: Cepheranthine
Antiproliferative activity against human HCC70 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human HCC70 assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 33226219]
HEK-293T CC50
2.1 μM
Compound: 3; cep
Cytotoxicity against HEK293T cells assessed as reduction in cell viability by CellTiter-Glo assay
Cytotoxicity against HEK293T cells assessed as reduction in cell viability by CellTiter-Glo assay
[PMID: 37043739]
HeLa IC50
1.53 μM
Compound: Cepharanthine
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
Inhibition of Ebolavirus glycoprotein/matrix protein VP40 entry in human HeLa cells after 4.5 hrs beta-lactamase reporter assay
[PMID: 29624387]
HL-60 IC50
9.2 μM
Compound: 7
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
Cytotoxicity against human HL60 cells after 48 hrs by MTS assay
[PMID: 23621840]
HT-1080 ED50
6.1 μg/mL
Compound: 11
Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human HT1080 cells after 3 days by sulforhodamine B assay
[PMID: 8450319]
KB ED50
5.9 μg/mL
Compound: 11
Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay
Cytotoxicity against human KB cells after 3 days by sulforhodamine B assay
[PMID: 8450319]
KB ED50
9700 nM
Compound: 12
Cytotoxicity against human KB cells after 72 hrs by SRB assay
Cytotoxicity against human KB cells after 72 hrs by SRB assay
[PMID: 9917283]
KB-V1 ED50
0.9 μg/mL
Compound: 11
Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human KBV1 cells after 3 days by sulforhodamine B assay
[PMID: 8450319]
LNCaP ED50
5.6 μg/mL
Compound: 11
Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay
Cytotoxicity against human LNCAP cells after 3 days by sulforhodamine B assay
[PMID: 8450319]
MCF7 IC50
2.9 μM
Compound: 7
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 48 hrs by MTS assay
[PMID: 23621840]
MDA-MB-231 GI50
5.3 μM
Compound: Cepheranthine
Antiproliferative activity against human MDA-MB-231 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 33226219]
MDA-MB-453 GI50
5.5 μM
Compound: Cepheranthine
Antiproliferative activity against human MDA-MB-453 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human MDA-MB-453 assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 33226219]
MOLT-4 CC50
10 μg/mL
Compound: CEP, Cepharanthine
Cytotoxicity against human MOLT4 cells assessed as cell growth inhibition after 24 hrs by MTT assay
Cytotoxicity against human MOLT4 cells assessed as cell growth inhibition after 24 hrs by MTT assay
[PMID: 24704028]
P388 ED50
0.3 μg/mL
Compound: 11
Cytotoxicity against mouse P388 cells after 2 days by sulforhodamine B assay
Cytotoxicity against mouse P388 cells after 2 days by sulforhodamine B assay
[PMID: 8450319]
SJRH30 GI50
3.8 μM
Compound: Cepheranthine
Antiproliferative activity against human SJRH30 assessed as cell growth inhibition after 48 hrs by SRB assay
Antiproliferative activity against human SJRH30 assessed as cell growth inhibition after 48 hrs by SRB assay
[PMID: 33226219]
SK-MEL-2 ED50
14.5 μg/mL
Compound: 11
Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human SK-MEL-2 cells after 3 days by sulforhodamine B assay
[PMID: 8450319]
SMMC-7721 IC50
9.9 μM
Compound: 7
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
Cytotoxicity against human SMMC7721 cells after 48 hrs by MTS assay
[PMID: 23621840]
SW480 IC50
4.7 μM
Compound: 7
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
Cytotoxicity against human SW480 cells after 48 hrs by MTS assay
[PMID: 23621840]
U-937 IC50
> 50 μM
Compound: 8, NSC 623442
Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay
Cytotoxicity against human U937 cells after 24 hrs by alamar blue assay
[PMID: 22766217]
Vero CC50
> 50 μM
Compound: Cepharanthine
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
Cell viability measured by CellTiter-Glo assay in Vero cells at MOI 0.05 after 72hr
10.1101/2020.03.20.999730
Vero IC50
4.47 μM
Compound: Cepharanthine
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
Antiviral activity against SARS-CoV-2 (viral titer) measured by plaque assay in Vero cells at MOI 0.0125 after 24 hr
10.1101/2020.03.20.999730
ZR-75-1 ED50
1.2 μg/mL
Compound: 11
Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay
Cytotoxicity against human ZR-75-1 cells after 3 days by sulforhodamine B assay
[PMID: 8450319]
體外研究
(In Vitro)

Cepharanthine (CEP) (2 μM，48 小時(shí)) 抑制細(xì)胞活力和集落形成，并通過(guò)線粒體途徑誘導(dǎo)人 TNBC 細(xì)胞凋亡[2]。
Cepharanthine (2 μM，48 小時(shí)) 會(huì)損害 MDA-MB-231 細(xì)胞中線粒體的功能，導(dǎo)致線粒體分裂和凋亡[2]。
Cepharanthine (5 μM，24 小時(shí)) 可增強(qiáng) K562 細(xì)胞 對(duì)抗癌劑 Doxorubicin (HY-15142A) 和 Vincristine (HY-N0488) 的敏感性，并可增強(qiáng)抗癌劑誘導(dǎo)下的凋亡[2]。
Cepharanthine (10-50 μM，0.5-1 h) 通過(guò)抑制細(xì)胞質(zhì)細(xì)胞器的酸化改變了 K562 細(xì)胞中 Doxorubicin (HY-15142A) 從細(xì)胞質(zhì)液泡到核質(zhì)的分布[3]。
Cepharanthine (0-50 μM，30 min) 在體外顯示出對(duì)人肝細(xì)胞色素 P450 酶 CYP3A4，CYP2E1 和 CYP2C9的抑制作用[4]。
Cepharanthine (0-4 μM，48 小時(shí)) 阻止惡性瘧原蟲(chóng)在環(huán)狀階段的發(fā)育，對(duì) FCM29，W2，3D7 和 K1 的IC50 分別為 3.059，0.927，2.276 和 1.803 μM[5]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis[2]

Cell Line: MDAMB-231 and BT549 cells
Concentration: 2 μM
Incubation Time: 48 h
Result: Cepharanthine alone minimally increased apoptosis (~5% to ~10%), whereas combinated with Epirubicin (HY-13624) markedly increased apoptosis (~50%).

Western Blot Analysis[2]

Cell Line: MDAMB-231 cells
Concentration: 2 μM
Incubation Time: 48 h
Result: Combinated with Epirubicin (HY-13624) markedly resulted in oxidation of the actin-remodeling protein cofilin, which promoted formation of an intramolecular disulfide bridge between Cys39, Cys80 and Ser3 dephosphorylation, leading to mitochondria translocation of cofilin.
Combinated with Epirubicin (HY-13624) induced mitochondrial fission in MDA-MB-231 cells.

Immunofluorescence[3]

Cell Line: K562 cells or MIA-PaCa-2 cells
Concentration: 10,20,25,50 μM
Incubation Time: 0.5 h or 1 h
Result: Made the intracellular localization of Doxorubicin (HY-15142A) in cytoplasmic vesicles shifted to the nucleoplasm.
Decreased red AO (weakly basic fluorescence probe) fluorescence by dose-dependent mannar in K562 cells.

Cell Viability Assay[5]

Cell Line: P. falciparum cultivated in type A+ human erythrocytes
Concentration: 2 μM
Incubation Time: 48 h
Result: Blocked P. falciparum development in ring stage with IC50s of 3.059, 0.927, 2.276, and 1.803 μM for FCM29, W2, 3D7 and K1, respectively.
體內(nèi)研究
(In Vivo)

Cepharanthine (CEP) (12 mg/kg，腹腔注射，每日 1 次，持續(xù) 36 天) 增強(qiáng) Epirubicin (HY-13624) 在 MDA-MB-231 細(xì)胞異種移植物中的治療效果[2]。
Cepharanthine (10 mg/kg，腹腔注射，單次給藥) 通過(guò)抑制白細(xì)胞活化來(lái)預(yù)防 LPS 誘導(dǎo)的大鼠肺血管損傷[6]。
Cepharanthine (10 mg/kg，腹腔注射，單次給藥) 通過(guò) NF-kB 抑制 LPS 誘導(dǎo)的大鼠全身炎癥模型發(fā)揮抗炎作用[7]。
Cepharanthine (20-180 mg/kg，腹腔注射) 在小鼠疼痛模型可產(chǎn)生劑量依賴性鎮(zhèn)痛作用，ED50 值為 24.5 mg/kg [8]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: MDA-MB-231 cell xenografts in mice[1]
Dosage: 12 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 36 days
Result: Combinated with Epirubicin (HY-13624) greatly enhanced the therapeutic efficacy compared with administration of either drug alone.
Animal Model: LPS-induced pulmonary vascular injury in male Wistar rats[6]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Decreased LPS-induced pulmonary vascular injury.
Significantly inhibited the increases in plasma tumor necrosis factor-a (TNF-a) concentrations.
Animal Model: LPS-induced Wistar rat model of systemic inflammation[7]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection (i.p.), single dose
Result: Significantly inhibited the increase in LPS-induced IL-6, TNF-α and nitrate/nitrite levels.
Reduced interstitial edema and inflammatory cell compared with the control group.
Reduced pathologic abnormalities, such as vacuolization, dot necrosis, striped necrosis, and bridging necrosis appeared, and inflammatory cells compared with the control group.
group compared with the LPS group.
Animal Model: Mice pain models in Kunming (KM) strain male and female mice [8]
Dosage: 10 mg/kg
Administration: Intraperitoneal injection (i.p.)
Result: Resulted in a dose-dependent antinociceptive effect with an ED50 value of 24.5 mg/kg in mice pain models.
Significantly decreased the intestinal propulsion with maximal inhibition at 33.6%.
Clinical Trial
分子量

606.71

Formula

C37H38N2O6
CAS 號(hào)
性狀

固體

顏色

White to yellow

中文名稱

千金藤堿；千金藤素
結(jié)構(gòu)分類
初始來(lái)源
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.
儲(chǔ)存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn)： 

DMSO 中的溶解度 : 50 mg/mL (82.41 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 1.6482 mL 8.2412 mL 16.4823 mL
5 mM 0.3296 mL 1.6482 mL 3.2965 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

  • 方案 一

    請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (4.12 mM); 懸濁液; 超聲助溶

    此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。
  • 方案 二

    請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (3.43 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL（飽和度未知）的澄清溶液。

    以 1 mL 工作液為例，取 100 μL 20.8 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。

以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶。

  • 方案 一

    請(qǐng)依序添加每種溶劑： 50% PEG300    50% Saline

    Solubility: 6.02 mg/mL (9.92 mM); 懸濁液; 超聲助溶

  • 方案 二

    請(qǐng)依序添加每種溶劑： 15% Cremophor EL    85% Saline

    Solubility: 6.02 mg/mL (9.92 mM); 懸濁液; 超聲助溶

動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只
由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.91%

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.6482 mL 8.2412 mL 16.4823 mL 41.2058 mL
5 mM 0.3296 mL 1.6482 mL 3.2965 mL 8.2412 mL
10 mM 0.1648 mL 0.8241 mL 1.6482 mL 4.1206 mL
15 mM 0.1099 mL 0.5494 mL 1.0988 mL 2.7471 mL
20 mM 0.0824 mL 0.4121 mL 0.8241 mL 2.0603 mL
25 mM 0.0659 mL 0.3296 mL 0.6593 mL 1.6482 mL
30 mM 0.0549 mL 0.2747 mL 0.5494 mL 1.3735 mL
40 mM 0.0412 mL 0.2060 mL 0.4121 mL 1.0301 mL
50 mM 0.0330 mL 0.1648 mL 0.3296 mL 0.8241 mL
60 mM 0.0275 mL 0.1374 mL 0.2747 mL 0.6868 mL
80 mM 0.0206 mL 0.1030 mL 0.2060 mL 0.5151 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Cepharanthine
目錄號(hào)：
HY-N6972
需求量：